emd 53998 has been researched along with pirfenidone in 1 studies
Studies (emd 53998) | Trials (emd 53998) | Recent Studies (post-2010) (emd 53998) | Studies (pirfenidone) | Trials (pirfenidone) | Recent Studies (post-2010) (pirfenidone) |
---|---|---|---|---|---|
112 | 0 | 9 | 1,094 | 102 | 883 |
Protein | Taxonomy | emd 53998 (IC50) | pirfenidone (IC50) |
---|---|---|---|
Transforming growth factor beta-1 proprotein | Mus musculus (house mouse) | 1.43 | |
Mothers against decapentaplegic homolog 3 | Mus musculus (house mouse) | 1.43 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Brown, L; Dallemagne, C; Endre, Z; Margolin, S; Miric, G; Taylor, SM | 1 |
1 other study(ies) available for emd 53998 and pirfenidone
Article | Year |
---|---|
Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; Blood Glucose; Body Weight; Calcium Chloride; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Drinking; Eating; Fibrosis; Glomerular Filtration Rate; Heart Ventricles; In Vitro Techniques; Kidney; Male; Mineralocorticoid Receptor Antagonists; Myocardial Contraction; Myocardium; Norepinephrine; Pyridones; Quinolines; Rats; Rats, Wistar; Spironolactone; Thiadiazines; Vasoconstriction; Vasoconstrictor Agents | 2001 |